Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Many efficacy and safety claims are unsupported or only partially supported by the provided label excerpts, and several specific quantitative statements (percentages and incidence ranges) are not present in the supplied labeling text.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a prescription medication used to lower cholesterol levels.
Section 1.2 (Hypeerlipidemia) indicates LIPITOR is used as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG and to increase HDL-C.
Lipitor works by inhibiting the enzyme HMG-CoA reductase.
Section 12.1 (Mechanism of Action): selective, competitive inhibitor of HMG-CoA reductase.
Lipitor reduces low-density lipoprotein (LDL) or 'bad' cholesterol levels.
Section 1.2 and Section 14.2/12.1 excerpts state LIPITOR reduces LDL-C.
Lipitor reduces triglycerides.
Section 1.2 indicates reduction in TG; Section 14.2/14.3 excerpts also reference reductions in TG.
Lipitor increases high-density lipoprotein (HDL) or 'good' cholesterol levels.
Section 1.2 indicates increase in HDL-C; Section 14.2 excerpt states increases in HDL-C.
Unsupported Statements
Lipitor is used to prevent cardiovascular disease.
The label excerpt supports prevention of cardiovascular disease via specified outcomes (e.g., myocardial infarction and stroke), but the statement is too general and does not specify label-listed indications.
By blocking HMG-CoA reductase, Lipitor reduces the liver's ability to produce cholesterol.
Section 12.1 confirms HMG-CoA reductase inhibition but the provided excerpts do not explicitly state 'reduces the liver's ability to produce cholesterol.'
Lipitor reduces the risk of heart disease and stroke.
Label excerpt lists reductions in specific risks (e.g., myocardial infarction and stroke), not 'heart disease' broadly.
Lipitor reduces the risk of major cardiovascular events by 22% compared to placebo.
No quantitative 22% reduction statement appears in the provided label excerpts.
Lipitor improves blood lipid profiles.
The excerpts support specific lipid changes (total-C/LDL-C/TG/HDL-C/apo B), but 'improves blood lipid profiles' is not a specific labeled claim.
In patients with high cholesterol, Lipitor reduced LDL cholesterol by an average of 40–50%.
No provided label excerpt includes an average LDL-C reduction range of 40–50%.
In patients with high cholesterol, Lipitor increased HDL cholesterol by an average of 5–10%.
No provided label excerpt includes an average HDL-C increase range of 5–10%.
In patients with high cholesterol, Lipitor reduced triglyceride levels by an average of 20–30%.
No provided label excerpt includes an average TG reduction range of 20–30%.
Lipitor can cause muscle pain and weakness.
The label excerpt provided includes muscle-related adverse events (myalgia, myopathy/rhabdomyolysis), but does not explicitly pair 'muscle pain and weakness' as stated.
Muscle pain and weakness are common side effects of Lipitor, affecting up to 10% of patients taking the medication.
Section 6.1 excerpt lists discontinuation adverse reaction rates (e.g., myalgia 0.7%) and other commonly reported adverse reactions (>=2%), but does not provide 'up to 10%' for muscle pain/weakness.
Muscle pain and weakness associated with Lipitor are often reversible.
No 'reversible' statement appears in the provided label excerpts.
Liver damage is a rare but serious side effect of Lipitor, affecting less than 1% of patients taking the medication.
The provided excerpt includes liver enzyme increases and reports incidence for persistent elevations, but does not state 'liver damage' as a rare side effect with a 'less than 1%' incidence.
Lipitor can increase the risk of diabetes.
No diabetes risk statement appears in the provided label excerpts.
Lipitor can cause cognitive impairment.
Section 6.2 postmarketing experience includes 'memory impairment,' which is related to cognition; however the exact claim 'cognitive impairment' is not directly stated in the provided excerpts.
Lipitor typically starts working within 2–4 weeks of treatment.
No onset timing statement (2–4 weeks) appears in the provided label excerpts.
Lipitor may not be suitable for patients with liver disease.
The label excerpts support contraindication in 'active liver disease' (Section 4.1 and Section 8.6), but the statement is vague ('liver disease') and does not match the labeled 'active liver disease' contraindication.
Lipitor is not recommended for pregnant or breastfeeding women.
Label excerpts state pregnancy is contraindicated (Section 4.3 and 8.1) and nursing mothers should not breastfeed (Section 4.4 and 8.3). The 'not recommended' phrasing is less precise than the contraindication/advice in the provided excerpts.
Lipitor may interact with blood thinners.
The provided drug interaction excerpts mention fibric acid derivatives, niacin, cyclosporine, strong CYP3A4 inhibitors (including clarithromycin, certain protease inhibitors, itraconazole), and grapefruit juice, but do not mention blood thinners specifically.
Lipitor may interact with certain antibiotics.
The provided excerpts specifically mention clarithromycin (an antibiotic) and recommend caution; however the claim 'certain antibiotics' is not limited to label-listed antibiotics in the provided text.
Lipitor was first approved by the FDA in 1997.
No FDA approval-date statement is included in the provided label excerpts.
Lipitor's patent expired in 2011, allowing generic versions to enter the market.
No patent-expiration/generic-entry date is included in the provided label excerpts.
Contradictions
Low
AI Statement
Lipitor is not recommended for pregnant or breastfeeding women.
Label Reference
Contraindications: Section 4.3 (Pregnancy) states women who are pregnant or may become pregnant are contraindicated; Section 4.4 and 8.3 state women requiring LIPITOR should not breastfeed.
Important Omissions
No dose/administration details from Section 2 (e.g., starting dose, dosing range, timing with/without food) are provided in the AI claims.
Importance:
Moderate
No mention of key contraindications beyond pregnancy/nursing (e.g., active liver disease and hypersensitivity) despite other safety-related claims being made.
Importance:
Moderate
No mention of label-supported monitoring instructions such as liver function tests prior to and at 12 weeks following initiation and after dose increases.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims include unsupported quantitative risks/percentages and vague/general safety statements (e.g., diabetes risk, cognitive impairment, reversibility, liver disease suitability) that are not confirmed by the provided excerpts; pregnancy/nursing language is imprecise relative to contraindication/advice, which could affect risk understanding.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Numerous efficacy and safety claims contain unsupported quantitative details or are not directly supported by the provided label excerpts (including diabetes risk, onset timing, reversal, incidence rates, and specific percentages).
Suggested Improvement
Restrict claims to label-excerpt-supported statements (e.g., specific indication outcomes, mechanism, specific lipid changes, and label-listed adverse reactions/interactions) and remove or qualify unsupported quantitative/statistical assertions and non-excerpted facts (approval date, patent expiration).